舒泰神：关于BDB-001注射液（ANCA相关性血管炎适应症）获得Ⅰ/Ⅱ期临床研究总结报告的公告

Core Viewpoint - The company Shuyou Shen announced the acquisition of a summary report for the Phase I/II clinical study of BDB-001 injection, which is aimed at treating ANCA-associated vasculitis (AAV) [2] Group 1 - The announcement was made on the evening of July 31 [2] - The clinical study report pertains to the drug BDB-001, which targets ANCA-associated vasculitis [2]